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Background: Sphingolipids are synthesized from very long-chain fatty acids and sphingoid bases.
Results: Rom2 controls Elo2 phosphorylation to regulate very long-chain fatty acid synthesis.
Conclusion:Distinct signaling pathways emanating from the plasmamembrane regulate the different branches of sphingolipid
synthesis.
Significance: Signaling from the plasmamembrane regulates a key step in sphingolipid synthesis, required for lipid homeostasis
of the plasma membrane.
Sphingolipids are essential components of eukaryotic mem-
branes, where they serve to maintain membrane integrity. They
are important components of membrane trafficking and func-
tion in signaling asmessengermolecules. Sphingolipids are syn-
thesized de novo from very long-chain fatty acids (VLCFA) and
sphingoid long-chain bases, which are amide linked to form cer-
amide and further processed by addition of various headgroups.
Little is known concerning the regulation of VLCFA levels and
how cells coordinate their synthesis with the availability of long-
chain bases for sphingolipid synthesis.Herewe show that Elo2, a
key enzymeofVLCFA synthesis, is controlled by signaling of the
guanine nucleotide exchange factor Rom2, initiating at the
plasmamembrane.This pathway controls Elo2phosphorylation
state andVLCFAsynthesis.Ourdata identify a regulatorymech-
anism for coordinating VLCFA synthesis with sphingolipid
metabolism and link signal transduction pathways from the
plasma membrane to the regulation of lipids for membrane
homeostasis.
Eukaryotic membranes are composed primarily of lipids
from three classes: glycerophospholipids, sterols, and sphingo-
lipids (SLs).3 SLs are enriched in the outer leaflet of the plasma
membrane (1–3). Together with sterols, they formmore tightly
packed bilayers compared with membranes composed only of
glycerophospholipids, and thus help to seal the membrane and
isolate the cytoplasm from the extracellular environment (4).
SLs are also capable of forming nano-domains with sterols in
the membrane, which may organize proteins for cell signaling
(e.g. from the plasmamembrane) or for vesicular trafficking (e.g.
from the trans-Golgi network) (5–9). In addition, several inter-
mediates of SL metabolism, such as sphingosine 1-phosphate
and ceramide, function as messenger signaling molecules
within and between cells (10, 11).
Surprisingly little is known regarding the regulation of SL
abundance in membranes. Much of the current knowledge is
derived from studies of the yeast Saccharomyces cerevisiae,
which has been an excellent model system to dissect the prin-
ciples of SL regulation. Although there are substantial differ-
ences in SLs between yeast andmammals (e.g. in the lipid head-
groups), general aspects of SL metabolism, including key
enzymes and regulatory features, are evolutionary conserved
(12–16). As in metazoans, including humans, SL synthesis in
yeast occurs in two branches that provide VLCFAs (saturated
fatty acids containing 20–26 carbon atoms) and sphingoid
long-chain bases. These two components are joined to form
ceramides, which then gain headgroups consisting of inositol
phosphate and mannose to form complex sphingolipids (11)
(Fig. 1A). In yeast, the essential function of SLs appears to be
mediated by the VLCFA component. Yeast that lack SLs can
survive by complementation with mutations that incorporate
VLCFAs into membrane phospholipids, where they are nor-
mally not found (17).
The abundance of the VLCFA and sphingoid long-chain
bases must be balanced by cells to provide adequate substrates
for SL synthesis. The first and rate-limiting step of sphingoid
long-chain base synthesis is the condensation of serine with
palmitoyl-CoA, catalyzed by serine palmitoyltransferase (SPT,
encoded by LCB1, LCB2, and TSC3 in yeast). When cells have
sufficient levels of SLs, SPT activity is inhibited by formation of
an inhibitory complex with Orm1 or Orm2 (Orm1/2 proteins).
When SL levels fall in the plasma membrane, a signaling cas-
cade initiated by Slm1/2 protein-mediated control of TORC2
leads to the phosphorylation of Orm1/2 through the interme-
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diate Ypk1/2 kinases (18–23). Orm1/2 phosphorylation in turn
dissociates the proteins from SPT, relieving their inhibition of
the enzyme and increasing SL synthesis. In addition, Ypk1/2-
kinases activate ceramide synthase through phosphorylation,
thereby catalyzing the subsequent step in SL synthesis (24).
Little is yet known how regulation of different steps in SL
synthesis is coordinated. For instance, it is unclear how the
activity of the two initial branches of SL biosynthesis, providing
sphingoid long-chain bases and VLCFAs, are coordinated.
Knowledge of conserved SL regulation mechanisms would
enhance our understanding of the regulation of membrane lip-
ids in cells, and could also impact therapies for pathological
conditions where SL levels are altered, including the metabolic
syndrome and insulin resistance (25) or cancer (26) .
Here we utilized a combination of yeast genetics and quanti-
tative mass spectrometry to unravel important regulation of
Elo2, one of two elongases catalyzing the first and rate-limiting
step of VLCFA synthesis (27, 28). This regulation occurs
through Elo2 phosphorylation in a signaling pathway con-
trolled by the guanine nucleotide exchange factor Rom2.
EXPERIMENTAL PROCEDURES
Yeast Strains and Plasmids—All yeast strains used in this
study are listed in Table 1. All plasmids used are listed in Table
2. ELO2was cloned in the integrating plasmid pRS306 and Elo2
phosphorylation sites Thr334, Ser336, and Ser338 were mutated
to either alanine or aspartate using standard procedures. Plas-
mids were integrated at theURA3 locus in elo2 or elo2elo3
mutants.
Yeast Culture and Drug Treatment—Yeast cells were grown
according to standard procedures in synthetic complete (SC) or
rich (YPD) media at 30 °C. Myriocin (Sigma) was dissolved in
methanol and used at 0.75 or 0.25 M (liquid growth assays), 1
M (solidmedium), and 5M (liquidmedium). Fenpropimorph
(AccuStandard, Inc.) was dissolved in ethanol and used at 0.6
M. Growth in liquid media was assessed with the Bioscreen C
MBR system (Oy Growth Curves Ab Ltd.).
Phosphoproteomics—Enrichment of phosphorylated pep-
tides was performed as described previously with minor modi-
fications (29). Briefly, 500 ml of cells from “heavy” and “light”
labeled cultures with A600  0.7 were harvested and lysed in a
buffer containing 100mMTris, pH 9, 0.1 mMDTT, and 5% SDS
at 55 °C. Extracts were mixed one to one and proteins were
digested with the endoproteinase LysC following the protocol
for filter aided sample preparation (30). The resulting peptides
were desalted using Sep-Pak C18 cartridges (Waters). The pep-
tide mixture was acidified by addition of TFA and subjected to
phosphopeptide enrichment on TiO2 beads as described (29).
After elution, the six samples were combined to three samples
TABLE 1
Yeast strains used in this study
Strain Genotype Reference
TWY70 MATa his3 leu2 lys2 ura3 56
MATa elo2::KANR his31; leu20; ura30; met150 57
MATa elo3::KANR his31; leu20; ura30; met150 57
MATa ifa38::KANR his31; leu20; ura30; met150 57
MATa PHS1DAMP::KANR his31; leu20; ura30; met150 54
MATa TSC13DAMP::KANR his31; leu20; ura30; met150 54
MATa rom2::KANR his31; leu20; ura30; met150 57
MATa sac7::KANR his31; leu20; ura30; met150 57
MATa bck1::KANR his31; leu20; ura30; met150 57
MATa mkk1::KANR his31; leu20; ura30; met150 57
MATa mkk2::KANR his31; leu20; ura30; met150 57
MATa slt2::KANR his31; leu20; ura30; met150 57
MATa wsc1::KANR his31; leu20; ura30; met150 57
MATa wsc2::KANR his31; leu20; ura30; met150 57
MATa wsc3::KANR his31; leu20; ura30; met150 57
MATa mtl1::KANR his31; leu20; ura30; met150 57
MATa mid2::KANR his31; leu20; ura30; met150 57
TWY1050 MAT  lys2::NATR ura3–52 trp12 leu2–3112 his3–11 ade2–1 can1–100 This study
TWY2594 MATa his3 leu2 lys2 ura3 prs416::URA This study
TWY2595 MATa his3 leu2 lys2 ura3 pYE352_ypk2D239A::URA This study
TWY2596 MATa his3 leu2 lys2 ura3 YCp50_pkc1R398P::URA This study
TWY3181 MAT  lys2::NATR ura3–52 trp12 leu2–3112 his3–11 ade2–1 can1–100 elo2::HPHR This study
TWY3186 MATa ura3–52 trp12 leu2–3112 his3–11 ade2–1 can1–100 elo3::HPHR This study
TWY3187 MAT  lys2::NATR ura3–52 trp12 leu2–3112 his3–11 ade2–1 can1–100 elo2::HPHR
pRS306::URA
This study
TWY3188 MAT  lys2::NATR ura3–52 trp12 leu2–3112 his3–11 ade2–1 can1–100
elo2::HPHR, pRS306_ELO2::URA
This study
TWY3189 MAT  lys2::NATR ura3–52 trp12 leu2–3112 his3–11 ade2–1 can1–100 elo2::HPHR
pRS306_elo2T334A,S336A,S338A::URA
This study
TWY3190 MAT  lys2::NATR ura3–52 trp12 leu2–3112 his3–11 ade2–1 can1–100
elo2::HPHR, pRS306_elo2T334D,S336D,S338D::URA
This study
TWY3442 MAT a his31 leu20 lys20 ura30 ORM1-HA::HIS This study
TWY3446 MAT a his31 leu20 lys20 ura30 SLT2-HA::HIS This study
TWY3693 MAT  lys2::NATR ura3–52 trp12 leu2–3112 his3–11 ade2–1 can1–100
rom2::HPHR
This study
TWY3694 MAT  lys2::NATR ura3–52 trp12 leu2–3112 his3–11 ade2–1 can1–100 elo2::HPHR
pRS306_elo2T334A,S336A,S338A::URA rom2::KANR
This study
TWY3695 MAT  lys2::NATR ura3–52 trp12 leu2–3112 his3–11 ade2–1 can1–100 elo2::HPHR
pRS306_elo2T334D,S336D,S338D::URA rom2::KANR
This study
TWY3696 MAT  ura3–52 trp12 leu2–3112 his3–11 ade2–1 can1–100 mck1::NATR This study
TWY3697 MAT  ura3–52 trp12 leu2–3112 his3–11 ade2–1 can1–100 slt2::KANR This study
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bymixing two fractions. The samples were dried in a SpeedVac
to a final volumeof 2ml andbufferA (0.1% formic acid inwater)
was added to a final volume of 6 ml. 5 ml were analyzed by
online nanoflow liquid chromatography tandem mass spec-
trometry on a Q-Exactive Orbitrap (Thermo) as described pre-
viously (31). Raw data were processed by the MaxQuant soft-
ware package as described previously with the addition of STY
phosphorylation as a variable modification (31).
GC/MS—GC/MS samples were prepared as in Ref. 32 and
analyzed as described in Ref. 33 with the following modifica-
tions. Briefly, cells in midlogarithmic growth phase (40 A600
units) grown in SC medium were harvested, washed with ice-
cold water, and lipids were extracted with methanol:chloro-
form (1:1). Lipids were dried and re-suspended in 1 ml of 1 M
methanolic HCl (Sigma) containing 5% (v/v) 2,2-dimethoxy-
propane (Sigma). Samples were purgedwith nitrogen and incu-
bated for 1 h at 80 °C. Samples were cooled to room tempera-
ture and fatty acid methyl esters (FAMEs) were extracted with
hexane, purged with nitrogen, and 2–5 l were used immedi-
ately for injection or stored at20 °C. GC/MS was performed
using an Agilent 7890A GC and Agilent 5975C inert MSD with
a J&W DB-XLB column (30 m  0.18-mm inner diameter,
0.18 m). The acquired spectra were analyzed using Chemsta-
tion version A.02.02 software (Agilent). Peak identity was
determined using VLCFAME standards (FAME mix C8-C24,
methyl heptadecanoate, methyl tricosanoate, Sigma) and pro-
filing against a database of known compounds.
Lipidomics—Cell were harvested from 20ml of exponentially
growing cultures in synthetic medium at 30 °C and washed in
water at 4 °C. Cell pellets were frozen immediately in liquid
nitrogen and thawed later by adding 155 mM NH4CH3CO2,
followed by cell disruption using zirconia beads (0.5 mm; Bio-
Spec Products). Lipids were extracted and analyzed using a
LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scien-
tific) equipped with a robotic nanoflow ion source TriVersa
NanoMate (Advion BioSciences Ltd.) as previously described
(34). Lipid species were annotated according to their sum com-
position as previously described (35).
Time Course of Slt2 Phosphorylation—Yeast cultures grown
overnight in SC media were diluted to A600  0.05. Cultures
were grown at 30 °C to A600 0.4 and myriocin was added to a
final concentration of 5 M and incubated at 30 °C. 10 ml of
culture were taken at each time point and harvested at 4 °C.
Pellets were snap frozen in liquid nitrogen and stored at
80 °C. Cells were lysed by bead beating at 4 °C in RIPA (25mM
Tris-Cl, pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 1% sodium
deoxycholate, 0.1% SDS) containing Roche Complete protease
inhibitor mixture (11873580001) and Roche PhosStop phos-
phatase inhibitor (04906837001). 30 g of protein/sample was
used for SDS-PAGE and Western blotting with phospho-
p44/42 MAPK (ERK1/2) (Thr202/Tyr204) antibody (Cell Sig-
naling, number 9101), anti-HA (Roche number 12CA5)
phosphoglycerate kinase monoclonal antibody (Novex num-
ber 22C5D8), goat anti-mouse IgG-HRP (Santa Cruz num-
ber sc-2005), goat anti-rabbit IgG-HRP (Santa Cruz number
sc-2004).
RESULTS
Components of the Cell Wall Integrity Signaling Pathway Are
Required for Cell Growth When Sphingolipid Synthesis Is
Compromised—Our previous work generating a genetic inter-
action map of factors involved in plasma membrane and lipid
metabolism revealed an important function for Rom2 in SL
regulation (36). Specifically, the genetic interaction pattern for
rom2 closely resembled those of mutations in early sphingo-
lipid synthesis enzymes, such as Elo2, Sur2, Lcb3, or Elo3 (Fig.
1B) (36). rom2 deletion also resulted in synthetic genetic
interactions with lcb3, sur2, dpl1 and ysr3, all encoding
enzymes of SL metabolism. Moreover, compared with wild-
type cells, rom2 mutants were growth impaired when the SL
metabolism was inhibited by myriocin, an SPT inhibitor (Fig.
1C). Based on these findings and the accumulation of sphingoid
long-chain bases and concomitant depletion of ceramides in
rom2 cells (36), we hypothesized that a signaling cascade
including Rom2 is important to regulate the abundance of
membrane SLs.
Rom2 is a component of the “cell wall integrity pathway” in
yeast (Fig. 1C) (37). This signaling pathway orchestrates
changes to the cell wall in response to changes in growth state
or stresses. In this pathway, Rom2 acts as the GTP exchange
factor for the small G-protein Rho1, which in turn regulates the
activity of protein kinase C1 (Pkc1) (38–40). Major effects of
Pkc1 aremediated by themitogen-activated protein kinase cas-
cade composed of Bck1, Mkk1, Mkk2 and the mitogen-acti-
vated protein (MAP) kinase Slt2.
To test whether Rom2 affects SL metabolism through cell
wall integrity signaling, we first tested null mutants of the
known sensors of cell wall integrity (Wsc1, Wsc2, Wsc3, Mtl1,
and Mid2) (41) in the presence of myriocin and found that
wsc1 andwsc2 cells were sensitive tomyriocin.wsc1 exhib-
ited the most sensitivity to myriocin, suggesting it is the key
sensor in regulating cell wall integrity pathway signaling when
sphingolipids are limiting (Fig. 1C).
The next step of the cell wall integrity pathway after the
plasma membrane sensors is the activation of Rho1. Because
Rom2 activates Rho1 by loading it with GTP (42), we predicted
that increasing Rho1 activity should result in the opposite phe-
notype as displayed by rom2 on myriocin containing plates.
Consistent with this prediction, deletion of the Sac7 GTPase
activating protein (43), which is predicted to increase the
amount of active Rho1GTP, led to the suppression of growth
inhibition by myriocin (Fig. 1C).
Downstream of Rho1, cell wall integrity signaling continues
through a kinase cascade. Consistent with an important role for
the initial Pkc1 kinase in maintaining SL levels, cells expressing
a constitutive active allele of Pkc1 (pkc1R398P) (40)were able to
overcome SL synthesis inhibition by myriocin, growing better
TABLE 2
Plasmids used in this study
Number Plasmid Reference
TWP355 pRS416 55
TWP124 CY676, YCp50_pkc1R398P 40
TWP317 pYE352_ypk2D239A 44
TWP96 pRS306 55
TWP706 pRS306_ELO2 This study
TWP707 pRS306_elo2T334A,S336A,S338A This study
TWP708 pRS306_elo2T334D,S336D,S338D This study
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than wild-type cells under the same conditions. The extent of
this suppression was similar to the effect of expressing a consti-
tutively active version of Ypk2 (ypk2D239A) (44), a kinase that
up-regulates sphingoid long-chain base synthesis by phosphor-
ylating Orm1/2 proteins (Fig. 1C).
We further systematically tested the effect of the deletion of
each downstream kinase of the cell wall integrity signaling cas-
cade on cell growth when SL synthesis is compromised. Dele-
tion of the effectorMAP kinase Slt2 led to lethality onmyriocin
containing plates. Similarly, bck1 cells were strongly growth
impaired on myriocin containing plates, whereas the effects
due to deletion of the genes encoding the redundant Mkk1 or
Mkk2 kinases were milder (Fig. 1C).
To further investigate the activity of the cell wall integrity
signaling pathway under SL-limiting conditions, we assayed
Slt2 activity by monitoring the phosphorylation state of the
kinase after myriocin treatment. Interestingly, Slt2 phosphory-
lation decreased and remained dephosphorylated for the dura-
tion of the experiment (Fig. 1D). As a control, we followed the
phosphorylation of Orm1. As expected, within 15 min of treat-
ment, an HA-tagged version of Orm1 was phosphorylated.
Rom2-dependent Phosphorylation of the Fatty Acid Elongase
Elo2—Based on the data on cell growth under SL limiting con-
ditions, we hypothesized that the Rom2-dependent signaling
cascade regulates SL synthesis. To investigate this, we used
phosphoproteomics to identify Rom2-dependent phosphory-
lation sites (Fig. 2A). To allow for the identification of Rom2-
dependent phosphorylation sites that are regulated during
sphingolipid depletion, we compared the phosphoproteome of
wild-type and rom2 cells aftermyriocin treatment, which effi-
ciently depletes all SL species (19). Among the 4068 phospho-
peptides identified, we found several candidate sites for
ROM2-dependent phosphorylation, including proteins with
established roles in lipid synthesis (Fig. 2B, supplemental Table
S1). Notably, a cluster of two phosphoserines and a phospho-
threonine in the C terminus of Elo2 (Thr334, Ser336, and Ser338)
contained the most significant outliers of dephosphorylated
peptides in rom2 cells (p value 1E-25; Fig. 2, B and C). We
next tested whether these sites were only phosphorylated in
myriocin-treated cells or also in basal conditions. Monitoring
the three sites bymass spectrometry-based proteomics showed
a decrease of all three Elo2 phosphorylation sites in rom2
mutants compared with wild-type cells in the absence of myri-
ocin (Fig. 3, A–C). These data are consistent with previous
reports that have identified these three Elo2 sites phosphory-
lated in exponentially growing wild-type yeast (phosphogrid)
(45).
Elo2 is the rate-limiting enzyme in the elongation of fatty
acids to VLCFAs. In addition to the decrease in phosphoryla-
tion of Elo2, we observed increased phosphorylation of the
TORC2 component Bit61 and the TORC2 target Ypk1 after
myriocin treatment in cells lacking Rom2 (Fig. 2B). These
changes suggest that alterations of SL metabolism modulate
TORC2 pathway signaling activity in rom2 cells.
Elo2 Phosphorylation Is Down-regulated during Inhibition of
Sphingolipid Synthesis—VLCFA synthesis is catalyzed by two
elongases, Elo2 and Elo3, in yeast. Elo2 prefers shorter chain
fatty acids as substrates (e.g. C16, C18) and elongates them to
acyl-chains maximally containing 24 carbon atoms (C24). Its
homologue Elo3 primarily elongates C24 to C26 fatty acids,
which are the major constituents of yeast SLs (28, 34). Conse-
quently, deletion of ELO3 results in the complete absence of
C26 fatty acids with increased C20-C24 levels, whereas elo2
mutation results in a significant decrease in all VLCFAs (28).
Because Elo3 acts on products of Elo2, we reasoned that Elo2
regulation could control overall VLCFAs for SL synthesis. Con-
sistent with this hypothesis, although Elo3 and Elo2 are highly
similar in sequence, Elo3 lacks the putative region of Elo2 that
we identified as phosphorylated (Fig. 2D).
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FIGURE 1. The cell wall integrity pathway is required for normal
growth under SL limiting conditions. A, schematic overview of the SL
biosynthetic pathway in yeast. Key enzymes are shown in red, key metab-
olites in black. Sphingoid long-chain base formation is inhibited by the
pharmacological agent myriocin. KDHS, keto-dihydrosphinganine; LCB,
sphingoid long-chain base; M(IP)2C, mannosyl-diinositolphosphorylcer-
amide. B, histograms of correlations between genetic interaction profiles
of ELO3, ELO2, and ROM2 and all other genes in the plasma membrane
epistatic mini-array profile (36). C, the CWI pathway governs normal
growth under SL limiting conditions. A schematic showing the CWI signal-
ing pathway beginning at the plasma membrane. Serial dilutions of con-
trol cells and cells harboring the indicated mutations were spotted on SC
plates or SC plates containing 1 M myriocin. D, Slt2 phosphorylation
decrease after myriocin treatment. Indicated yeast strains were grown to
mid-log phase, treated with myriocin (5 M), harvested at indicated time
points, and analyzed by SDS-PAGE and Western blotting.
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We tested this model by assaying for Elo2 phosphorylation
duringmyriocin treatment (Fig. 4A).Quantitative phosphopro-
teomic analysis showed that the phosphorylation abundance at
each phosphorylation site decreased strongly during 30 min of
myriocin treatment (Fig. 4, B andC). The decrease in the abun-
dance of the phosphorylated peptides of the Elo2 C-terminal
tail was not due to concomitant increased double or triple phos-
phorylation as the abundance of the corresponding peptides
decreased or did not change during the time of the myriocin
treatment (Fig. 4, B and C).
Elo2 Phosphorylation Decrease Is a Key Regulatory Response
during SL Synthesis Inhibition—If VLCFA synthesis is impor-
tant for maintaining cellular SL homeostasis, we expected a
growth phenotype formutants in the fatty acid elongation cycle
under SL limiting conditions. To test this prediction, we serially
diluted elo2, elo3, ifa38, tsc13-DAMP, and phs1-DAMP
cultures onto plates containing myriocin. We found that each
of the mutations suppressed the growth defect due to myriocin
(Fig. 5A). Among several possible interpretations, this might
indicate that limiting VLCFA synthesis reduces the accumula-
tion of a lipotoxic species accumulating in myriocin-treated
cells.
To test whether phosphorylation is important for the physi-
ological function of Elo2 during SL synthesis inhibition, we next
assayed mutants in which we replaced each of the co-regulated
phosphorylation sites with non-phosphorylatable alanine
(elo2AAA) or negatively charged, phosphomimicking aspartate
residues (elo2DDD). Among the mutants, elo2DDD cells mim-
icked the elo2 deletion phenotype, rescuing the cells’ growth
on myriocin-containing plates, although to a lesser extent than
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the null mutant (Fig. 5, B and C). This phenotype was due to a
defect in Elo2 regulation, but not its basal function, as elo2DDD
was growth impaired on fenpropimorph, an inhibitor of ergos-
terol biosynthesis, similar to wild-type cells (Fig. 5, B and C). In
contrast, and in agreementwith Elo2 activation by dephosphor-
ylation, expression of elo2AAA led to a similar growth pheno-
type onmyriocin containingmediumas expression ofwild-type
Elo2, which is dephosphorylated under these conditions (Fig. 5,
B and C).
Our findings contrast a recent report that concluded dephos-
phorylated Elo2 was inactive and rapidly degraded (45). How-
ever, C terminally tagged strains of Elo2 used in this earlier
study are not appropriately regulated during SL synthesis inhi-
bition (data not shown). Moreover, in constructing ELO2
alleles containing phosphosite mutations, Zimmermann et al.
(45) deleted the 3 UTR, which leads to strongly decreased
mRNA levels (70% decreased compared with wild-type, data
not shown), similarly to the situation in DAmP alleles (46),
likely explaining the observed severe lack of function of the
allele.
To further test whether mutation of the Elo2 phosphoryla-
tion sites impairs the regulated, but not the basal function of the
protein, we assayed the genetic interaction of the mutant with
elo3. As expected, the elo3elo2 double mutation was lethal
(47). In contrast, either elo2DDD or elo2AAA supported growth
in the absence of Elo3, showing that the mutant proteins main-
tain at least basal activity in the absence of regulation by phos-
phorylation (Fig. 5D).
Elo2 Phosphorylation Regulates Very Long-chain Fatty Acid
Levels—To test whether Elo2 phosphorylation modulates
VLCFA synthesis, we next analyzed the fatty acid composition
of Elo2 phosphositemutants by gas chromatography coupled to
mass spectrometry (GC-MS). As expected for the increased
activity of dephosphorylated Elo2, cells expressing the elo2AAA
mutant showed increased levels specifically of VLCFAs, with
themost pronounced effects apparent onC20 toC26 fatty acids
(Fig. 6A). Biochemical activity assays with lysates from cells
expressing either mutant failed to reveal significant differences
in specific VLCFA activity (data not shown), arguing that reg-
ulationmight occur at the level of substrate binding or localiza-
tion of the enzymes.
To test whether phosphorylation control is important to reg-
ulateVLCFAs during sphingolipid synthesis inhibition, we next
tested the effect of the different phosphosite mutants on fatty
acid levels duringmyriocin treatment.We found that wild-type
cells that cannot synthesize ceramides due to the limitation of
sphingoid long-chain bases during myriocin treatment up-reg-
ulate C26 fatty acid. Consistent with an important regulatory
function of Elo2 phosphorylation, both elo2AAA and elo2DDD
cells failed to respond to the myriocin challenge (Fig. 6B).
Together, these data argue that the Elo2 phosphorylation sites
are not important for basal activity but to regulate its activity in
response to myriocin treatment.
To determine the effects of VLCFA accumulation on the
global lipid profile, we next measured the cellular lipidomes of
the elo2 phosphosite mutants, elo2, and wild-type strains. In
these experiments, total ceramide and complex sphingolipid
levels in elo2AAA and elo2DDD were unaltered (Fig. 6C).
If increased VLCFAs do not lead to increased SL levels they
should be present in a different lipid pool. To our surprise, the
VLCFAs did not enter phospholipids (e.g. phosphatidylcholine,
phosphatidylethanolamine, or phosphatidylinositol), but
where almost exclusively found in cellular triacylglycerols and
sterol esters (Fig. 6C). These findings indicate that cells have the
ability to store excess VLCFAs, likely within cytosolic lipid
droplets. This increase in triacylglycerols containing VLCFA
did not significantly affect total TG content (Fig. 6C) or lipid
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droplet volume (data not shown). This reflects that even when
accumulating in TGs due to a defect in SL synthesis, VLCFAs
are still much less abundant than shorter chain fatty acids, such
as C18.
Rom2 Regulates Very Long-chain Fatty Acid Levels—Our
hypothesis that Rom2-dependent signaling regulates Elo2 pre-
dicts that VLCFAs are altered in rom2 cells. Consistent with
the model, GC-MS analysis revealed a significant increase in
C26 fatty acids in rom2when shorter VLCFAs did not appear
to be affected (Fig. 7A).
We next determined the contribution of Elo2 phosphoryla-
tion to Rom2-dependent regulation of SL synthesis. To directly
test whether Elo2 phosphorylation was responsible for the
VLCFA phenotype of rom2 cells, we measured fatty acid pro-
files of elo2AAA rom2 and elo2DDD rom2 cells. The phos-
phomimetic elo2DDD rescued the increase in C26 seen in
rom2 alone, whereas the non-phosphorylatable elo2AAA
aggravated the VLCFA accumulation. These data further sup-
port that Elo2 phosphorylation is a critical control point regu-
lated by Rom2-dependent signaling (Fig. 7B).
If Elo2 is the key downstream effector of Rom2-dependent
signaling, the phosphomimetic elo2DDDmutant should rescue
the severe growth defect of rom2 cells in the presence of
myriocin. If there are other, more critical regulated steps, we
expect no significant effect of expressing the phosphomimetic
mutants in rom2 cells. Testing these possibilities, we found
that elo2DDD significantly decreases the doubling time of
rom2 in liquid medium containing a low dose of myriocin.
This argues that Elo2 is indeed a critical node of Rom2-depen-
dent SL regulation. However, elo2DDD did not restore the
growth rate to that of WT cells, arguing that either the phos-
phomimetic allele is not fully recapitulating phosphorylation or
that additional regulation exists (Fig. 7C).
DISCUSSION
Here we identify Elo2 as a key regulation point of VLCFA
synthesis. Our findings link the upstream steps of the cell wall
integrity signaling cascade to control of Elo2 andVLCFA levels.
How does Rom2 regulate Elo2? In a likely scenario, the first
phase of signaling during SL limitation diminishes activity of
cell wall integrity sensors, such as Wsc1, in the plasma mem-
brane. This in turn down-regulates Rom2 activity toward Rho1
and the downstream signaling cascade. Thus, both Rom2-de-
pendent regulation of VLCFA and TORC2-dependent regula-
tion of sphingosine synthesis respond to changes of the plasma
membrane state (12). During myriocin treatment, TORC2
activity is increased, whereas Rom2 activity is decreased. Con-
sistent with this notion, Rom2 localization at the plasma mem-
brane is diminished during myriocin treatment (48). This sug-
gests that cells use the reciprocal regulation of both signaling
systems to fine-tune communication on the state of the plasma
membrane. Consistent with this notion of two parallel path-
ways, activation of Rho1 suppresses tor2mutations (43).
The second phase of signaling, transduction of the signal
from the plasma membrane to ER-localized Elo2, is complex.
As expected from down-regulating the cell wall integrity path-
way, we observed a decrease in phosphorylation of the terminal
kinase of the pathway, Slt2. However, we and others did not
observe changes in Elo2 phosphorylation in slt2 cells (data not
shown) (45). This suggests that the change in Rom2-dependent
phosphorylation of Elo2 does not involve the downstream cell
wall integrity pathway signaling kinases, such as Slt2. Instead,
the signal from RhoGTP may be transduced through another
one of its targets, the TORC1 complex (49). Control of TORC1
could relay the information on plasma membrane SL levels to
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Mck1, aGSK3-like kinase in yeast thatmediates Elo2phosphor-
ylation in the ER (45). Importantly, in other systems, Gsk3
kinases need a priming kinase, which phosphorylates one site of
the target, to fully phosphorylate the substrate (50). Thus, it
remains possible that yet another kinase downstream of Rom2
is involved and plays this priming function.
Although downstream effectors of the cell wall integrity
pathway, such as Slt2, are not required for the change in Elo2
phosphorylation due to myriocin treatment, we find that they
are, nonetheless, important for cell growth when sphingolipid
synthesis is inhibited. This suggests that the cell wall integrity
pathwaymay have other functions in the homeostatic response
regulating plasma membrane composition. Interestingly,
rom2 has decreased ceramides (36), whereas both long-chain
bases andVLCFAs are increased (Fig. 7A) (36), suggesting com-
ponents of this signaling cascade may be involved in the regu-
lation of ceramide synthase. Another possibility is regulation of
the transcription of the Elo2 kinase Mck1 (51).
Our data lead to a model in which Elo2 is regulated by phos-
phorylation in response to VLCFA levels. First, during times of
increaseddemandforVLCFAs,Elo2isactivatedbydephosphory-
lation. During times of excess VLCFAs levels, Elo2 is deacti-
vated by phosphorylation and VLCFAs are esterified and
stored. Rom2 and TORC2 appear to cooperate to provide
increased amounts of VLCFA and sphingoid long-chain base
substrates for ceramide synthesis. In thismodel, the function of
the Elo2 phosphorylation system is to adjust the flux through
the elongation cycle tomatch the activity of SPT for production
of ceramides. In the presence ofmyriocin, when cells are unable
to up-regulate sphingoid long-chain base synthesis through the
Orm1/2-system, increased VLCFA pools cannot drive SL syn-
thesis. Instead, in the absence of coordinated regulation of
other SL synthesis steps, VLCFAs are shunted toward triacyl-
glycerols and presumably stored in cytosolic lipid droplets. This
storage of VLCFAs may reflect a protective mechanism that
prevents the build-up of VLCFAs in the ER, whichmay be lipo-
toxic. Lipotoxicity could be due tomembrane property changes
inflicted by sphingolipid synthesis intermediates. Some of the
SL synthesis intermediates are also potent signaling molecules.
Sphingosine and ceramide, as well as their phosphorylated
derivatives, play crucial functions in proliferation control (10).
Providing adequate amounts of VLCFAs thus may prevent
unintended signaling due to a build-up of SL synthesis
intermediates.
Notably, our interpretation that dephosphorylated Elo2 is
active is opposite to the interpretation of a recent paper that
argued that phosphorylation inactivates Elo2 (45). This dis-
crepancy is likely due to complications of yeast strain construc-
tion. Zimmermann et al. (45) generated mutants in the phos-
phorylation sites at the very C terminus by replacing the
sequence encoding the last few amino acids and in the pro-
cesses deleting the 3 UTR of the corresponding messenger
RNA (data not shown). As a consequence, the mRNA tran-
scribed from this allele is strongly reduced, leading to the
observed lack of function of this allele. In addition, the C-ter-
minal tags used by Zimmermann et al. (45) next to the phos-
phorylation site in our hands impair the regulation of Elo2 (data
not shown).
The control of Elo2may bemost important when conditions
change for the cell. Internal changes of conditions are driven by
the cell cycle, for instance. The regulation of the cell wall integ-
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rity pathway by the cell cycle (37) thus may serve to assure
appropriate levels of sphingolipid synthesis when the plasma
membrane, containing the bulk of sphingolipids, expands.
External changes, such as temperature changes, affect mem-
brane properties, and require a homeostatic response. Consis-
tent with this, the cell wall integrity pathway and sphingolipid
synthesis are regulated by heat stress (52).
As salient features of SL metabolism, as well as its control,
appear evolutionary conserved, similar mechanisms of VLCFA
regulation might operate in other eukaryotes. Consistent with
this notion, human fatty acid elongases, such as ELOVL5, were
found to be phosphorylated in systematic analyses (phosida.
com). In addition, single point mutations in human ELOVL5
lead to development of neurodegenerative spinocerebellar
ataxia (53), suggesting sphingolipid homeostasis regulation
may have an important function in the human adult brain. It
will be interesting to determine whether ELOVL5 phosphory-
lation similarly governs VLCFAmetabolism inmammalian tis-
sues, and if so, which role this regulation plays in organismal
physiology.
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